世界の不安神経症・うつ病治療市場分析・成長予測(~2030):製品種類別、疾患種類別、流通チャネル別

【英語タイトル】Anxiety and Depression Treatment Market Research Report: By Product Type, Disorder Type, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030

P&S Market Researchが出版した調査資料(PS21JN029)・商品コード:PS21JN029
・発行会社(調査会社):P&S Market Research
・発行日:2021年3月
・ページ数:n/a
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,185 ⇒換算¥460,350見積依頼/購入/質問フォーム
5 UserUSD5,466 ⇒換算¥601,260見積依頼/購入/質問フォーム
Enterprise UserUSD7,174 ⇒換算¥789,140見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The World Health Organization (WHO) has designated October 10th as World Mental Health Day in order to raise awareness about such issues and lessen people’s hesitation in seeking treatment. As a result of such initiatives, the global anxiety and depression treatment market value is predicted to increase from $17,770.9 million in 2020 to $24,467.7 million by 2030, at a 3.3% CAGR between 2021 and 2030, according to the market research report.
Similarly, a program, named Better Outcomes in Mental Health Care (BOiMHC), and an organization, called Mental Health Association, have been formed to help the cause in Australia. Another such organization aiding the anxiety and depression treatment market growth with its support to patients and educational courses is the National Alliance on Mental Illness (NAMI), which was founded in the U.S. in 1979.

Due to the COVID-19 pandemic, the anxiety and depression treatment market reported negative impact. The lockdowns implemented around the world led to the shutting down of factories, which resulted in the low production of drugs and devices. Moreover, the restrictions on non-essential movement and international trade led to the curtailed supply of such products.

The highest CAGR in the anxiety and depression drugs market in the years to come is expected to be witnessed in the online channels category, on the basis of distribution channel. Because of the shopping convenience offered by such websites, allowing people to order from home, avail discounts, and receive doorstep delivery, customers are switching to them.

Presently, North America generates the highest revenue in the anxiety and depression treatment market due to the rising incidence of chronic pain, anxiety, and depression, increasing awareness regarding mental health, and growing number of people receiving prescriptions for the associated drugs and devices. In the years to come, the demand for such products will shoot up the fastest in Asia-Pacific (APAC). The prevalence of anxiety and depression is rising in the region owing to the booming population of the elderly.

Major companies in the global anxiety and depression treatment market are Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Johnson & Johnson, AbbVie Inc., Merck & Co. Inc., Eli Lilly and Company, Sanofi, Lundbeck A/S, GlaxoSmithKline plc, Mylan N.V, Glenmark Life Sciences Limited, Cipla Ltd., Lupin Limited, AstraZeneca plc, Amneal Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Intas Pharmaceuticals Ltd.

【レポートの目次】

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product Type
1.5.2 Drugs Market Segmentation by Disorder Type
1.5.3 Drugs Market Segmentation by Distribution Channel
1.5.4 Market Segmentation by Region
1.6 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 Publisher Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators
5.1 Prevalence of Mental Disorders

Chapter 6. Definition of Market Segments
6.1 By Product Type
6.1.1 Drugs
6.1.1.1 Antidepressants
6.1.1.1.1 SSRIs
6.1.1.1.2 SNRIs
6.1.1.1.3 TCAs
6.1.1.1.4 MAOIs
6.1.1.1.5 Others
6.1.1.2 Anticonvulsants
6.1.1.3 Atypical antipsychotics
6.1.1.4 Benzodiazepines
6.1.1.5 Beta-blockers
6.1.2 Devices
6.2 By Disorder Type
6.2.1 Major Depressive Disorder
6.2.2 OCD
6.2.3 Phobia
6.2.4 PTSD
6.2.5 Others
6.3 By Distribution Channel
6.3.1 Hospital Pharmacies
6.3.2 Retail Pharmacies
6.3.3 Online Channels
6.3.4 Direct Channels

Chapter 7. Industry Outlook
7.1 Market Dynamics
7.1.1 Trends
7.1.1.1 Increasing number of mergers and acquisitions
7.1.2 Drivers
7.1.2.1 Increasing aging population
7.1.2.2 Growing awareness about mental diseases and their treatment
7.1.2.3 Rising number of product approvals
7.1.2.4 Impact analysis of drivers on market forecast
7.1.3 Restraints
7.1.3.1 Side effects associated with usage of drugs and devices
7.1.3.2 Availability of complementary and alternative medicines
7.1.3.3 Impact analysis of restraints on market forecast
7.1.4 Opportunities
7.1.4.1 Emerging economies are key opportunity areas for market players
7.2 Impact of COVID-19
7.3 Porter’s Five Forces Analysis
7.3.1 Bargaining Power of Buyers
7.3.2 Bargaining Power of Suppliers
7.3.3 Intensity of Rivalry
7.3.4 Threat of New Entrants
7.3.5 Threat of Substitutes

Chapter 8. Global Market Size and Forecast
8.1 Overview
8.2 Market Revenue, by Product Type (2015-2030)
8.2.1 Drugs Market Revenue, by Type (2015-2030)
8.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
8.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
8.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
8.3 Market Revenue, by Region (2015-2030)

Chapter 9. North America Market Size and Forecast
9.1 Overview
9.2 Market Revenue, by Product Type (2015-2030)
9.2.1 Drugs Market Revenue, by Type (2015-2030)
9.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
9.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
9.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
9.3 Market Revenue, by Country (2015-2030)

Chapter 10. Europe Market Size and Forecast
10.1 Overview
10.2 Market Revenue, by Product Type (2015-2030)
10.2.1 Drugs Market Revenue, by Type (2015-2030)
10.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
10.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
10.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
10.3 Market Revenue, by Country (2015-2030)

Chapter 11. APAC Market Size and Forecast
11.1 Overview
11.2 Market Revenue, by Product Type (2015-2030)
11.2.1 Drugs Market Revenue, by Type (2015-2030)
11.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
11.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
11.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
11.3 Market Revenue, by Country (2015-2030)

Chapter 12. LATAM Market Size and Forecast
12.1 Overview
12.2 Market Revenue, by Product Type (2015-2030)
12.2.1 Drugs Market Revenue, by Type (2015-2030)
12.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
12.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
12.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
12.3 Market Revenue, by Country (2015-2030)

Chapter 13. MEA Market Size and Forecast
13.1 Overview
13.2 Market Revenue, by Product Type (2015-2030)
13.2.1 Drugs Market Revenue, by Type (2015-2030)
13.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
13.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
13.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
13.3 Market Revenue, by Country (2015-2030)

Chapter 14. U.S. Market Size and Forecast
14.1 Overview
14.2 Market Revenue, by Product Type (2015-2030)
14.2.1 Drugs Market Revenue, by Type (2015-2030)
14.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
14.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
14.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 15. Canada Market Size and Forecast
15.1 Overview
15.2 Market Revenue, by Product Type (2015-2030)
15.2.1 Drugs Market Revenue, by Type (2015-2030)
15.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
15.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
15.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 16. Germany Market Size and Forecast
16.1 Overview
16.2 Market Revenue, by Product Type (2015-2030)
16.2.1 Drugs Market Revenue, by Type (2015-2030)
16.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
16.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
16.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 17. France Market Size and Forecast
17.1 Overview
17.2 Market Revenue, by Product Type (2015-2030)
17.2.1 Drugs Market Revenue, by Type (2015-2030)
17.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
17.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
17.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 18. U.K. Market Size and Forecast
18.1 Overview
18.2 Market Revenue, by Product Type (2015-2030)
18.2.1 Drugs Market Revenue, by Type (2015-2030)
18.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
18.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
18.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 19. Italy Market Size and Forecast
19.1 Overview
19.2 Market Revenue, by Product Type (2015-2030)
19.2.1 Drugs Market Revenue, by Type (2015-2030)
19.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
19.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
19.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 20. Spain Market Size and Forecast
20.1 Overview
20.2 Market Revenue, by Product Type (2015-2030)
20.2.1 Drugs Market Revenue, by Type (2015-2030)
20.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
20.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
20.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 21. China Market Size and Forecast
21.1 Overview
21.2 Market Revenue, by Product Type (2015-2030)
21.2.1 Drugs Market Revenue, by Type (2015-2030)
21.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
21.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
21.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 22. Japan Market Size and Forecast
22.1 Overview
22.2 Market Revenue, by Product Type (2015-2030)
22.2.1 Drugs Market Revenue, by Type (2015-2030)
22.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
22.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
22.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 23. India Market Size and Forecast
23.1 Overview
23.2 Market Revenue, by Product Type (2015-2030)
23.2.1 Drugs Market Revenue, by Type (2015-2030)
23.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
23.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
23.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 24. Australia Market Size and Forecast
24.1 Overview
24.2 Market Revenue, by Product Type (2015-2030)
24.2.1 Drugs Market Revenue, by Type (2015-2030)
24.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
24.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
24.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 25. South Korea Market Size and Forecast
25.1 Overview
25.2 Market Revenue, by Product Type (2015-2030)
25.2.1 Drugs Market Revenue, by Type (2015-2030)
25.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
25.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
25.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 26. Brazil Market Size and Forecast
26.1 Overview
26.2 Market Revenue, by Product Type (2015-2030)
26.2.1 Drugs Market Revenue, by Type (2015-2030)
26.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
26.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
26.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 27. Mexico Market Size and Forecast
27.1 Overview
27.2 Market Revenue, by Product Type (2015-2030)
27.2.1 Drugs Market Revenue, by Type (2015-2030)
27.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
27.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
27.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 28. Saudi Arabia Market Size and Forecast
28.1 Overview
28.2 Market Revenue, by Product Type (2015-2030)
28.2.1 Drugs Market Revenue, by Type (2015-2030)
28.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
28.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
28.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 29. South Africa Market Size and Forecast
29.1 Overview
29.2 Market Revenue, by Product Type (2015-2030)
29.2.1 Drugs Market Revenue, by Type (2015-2030)
29.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
29.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
29.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 30. Competitive Landscape
30.1 List of Market Players and Their Offerings
30.2 Product Benchmarking
30.3 Recent Strategic Developments of Key Players
30.3.1 Product Launches and Approvals
30.3.2 Mergers and Acquisitions
30.3.3 Others

Chapter 31. Company Profiles
31.1 Novartis AG
31.1.1 Business Overview
31.1.2 Product and Service Offerings
31.1.3 Key Financial Summary
31.2 Pfizer Inc.
31.2.1 Business Overview
31.2.2 Product and Service Offerings
31.2.3 Key Financial Summary
31.3 Bristol-Myers Squibb Company
31.3.1 Business Overview
31.3.2 Product and Service Offerings
31.3.3 Key Financial Summary
31.4 Johnson & Johnson
31.4.1 Business Overview
31.4.2 Product and Service Offerings
31.4.3 Key Financial Summary
31.5 Merck & Co. Inc.
31.5.1 Business Overview
31.5.2 Product and Service Offerings
31.5.3 Key Financial Summary
31.6 AbbVie Inc.
31.6.1 Business Overview
31.6.2 Product and Service Offerings
31.6.3 Key Financial Summary
31.7 Eli Lilly and Company
31.7.1 Business Overview
31.7.2 Product and Service Offerings
31.7.3 Key Financial Summary
31.8 GlaxoSmithKline plc
31.8.1 Business Overview
31.8.2 Product and Service Offerings
31.8.3 Key Financial Summary
31.9 Sanofi
31.9.1 Business Overview
31.9.2 Product and Service Offerings
31.9.3 Key Financial Summary
31.10 H. Lundbeck A/S
31.10.1 Business Overview
31.10.2 Product and Service Offerings
31.10.2.1 Marketed products
31.10.2.2 Pipeline products
31.10.3 Key Financial Summary
31.11 Mylan N.V.
31.11.1 Business Overview
31.11.2 Product and Service Offerings
31.11.3 Key Financial Summary
31.12 Cipla Ltd.
31.12.1 Business Overview
31.12.2 Product and Service Offerings
31.12.3 Key Financial Summary
31.13 Glenmark Life Sciences Limited
31.13.1 Business Overview
31.13.2 Product and Service Offerings
31.13.3 Key Financial Summary
31.14 Lupin Limited
31.14.1 Business Overview
31.14.2 Product and Service Offerings
31.14.3 Key Financial Summary
31.15 Amneal Pharmaceuticals Inc.
31.15.1 Business Overview
31.15.2 Product and Service Offerings
31.15.3 Key Financial Summary
31.16 AstraZeneca plc
31.16.1 Business Overview
31.16.2 Product and Service Offerings
31.16.2.1 Marketed products
31.16.2.2 Pipeline products
31.16.3 Key Financial Summary
31.17 Sun Pharmaceutical Industries Ltd.
31.17.1 Business Overview
31.17.2 Product and Service Offerings
31.17.3 Key Financial Summary
31.18 Intas Pharmaceuticals Ltd.
31.18.1 Business Overview
31.18.2 Product and Service Offerings
31.18.3 Key Financial Summary
31.19 Sumitomo Dainippon Pharma Co. Ltd.
31.19.1 Business Overview
31.19.2 Product and Service Offerings
31.19.3 Key Financial Summary

Chapter 32. Appendix
32.1 Abbreviations
32.2 Sources and References
32.3 Related Reports



★調査レポート[世界の不安神経症・うつ病治療市場分析・成長予測(~2030):製品種類別、疾患種類別、流通チャネル別] (コード:PS21JN029)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の不安神経症・うつ病治療市場分析・成長予測(~2030):製品種類別、疾患種類別、流通チャネル別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆